Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al

Arthritis Rheum. 2003 Jan;48(1):282-3; author reply 283. doi: 10.1002/art.10628.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Letter

MeSH terms

  • Female
  • Humans
  • Male
  • Piperazines / therapeutic use*
  • Purines
  • Raynaud Disease / drug therapy*
  • Sildenafil Citrate
  • Sulfones
  • Vasodilator Agents / therapeutic use*

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate